ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells

Duan,Xiaohui; Mao,Xianhai; Sun,Weijia

doi:10.3892/mmr.2013.1272

ADAM15 is involved in MICB shedding and mediates the effects of gemcitabine on MICB shedding in PANC-1 pancreatic cancer cells

Authors:
- Xiaohui Duan
- Xianhai Mao
- Weijia Sun
View Affiliations

Affiliations: Department of Hepatobiliary Surgery, Hunan Provincial People's Hospital, Changsha 410005, P.R. China, Department of Gerneral Surgery, Xiangya Hospital, Central South University, Changsha 410008, Hunan, P.R. China
Published online on: January 11, 2013 https://doi.org/10.3892/mmr.2013.1272
Pages: 991-997

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

The aim of this study was to investigate the role of ADAM15 in MHC class I polypeptide-related sequence B (MICB) protein ectodomain shedding and observe whether or not gemcitabine affects MICB shedding from PANC-1 cells. In this study, immunohistochemistry of MICB and ADAM15 were performed on tumor samples obtained from 93 patients with pancreatic ductal adenocarcinoma (PDAC). The expression of MICB and ADAM15 in the PDAC tissues was significantly higher compared with that in the normal tissues of the pancreas. Statistical analysis showed a significant correlation between the expression of MICB and certain classic clinicopathological characteristics (i.e., histological grade and TNM stage). ADAM15 expression was found to correlate with lymph node metastasis and TNM stage. The Spearman's rank test suggested that the expression of MICB was inversely correlated with that of ADAM15 in PDAC tissues. Knockdown of ADAM15 in PANC-1 cells clearly upregulated MICB expression on the cellular surface and downregulated soluble MICB (sMICB) levels in the culture supernatants. A non-toxic dose of 0.5 µmol/l gemcitabine suppresses ADAM15 expression leading, at the same time, to an increase in MICB expression and a decrease in sMICB production in PANC-1 cells. The mRNA levels of MICB did not change following PANC-1 exposure to gemcitabine. Further study suggests that the suppressive effect of gemcitabine on MICB shedding in PANC-1 cells is mediated by ADAM15 downregulation. In conclusion, the results of the present study support the hypothesis that ADAM15 is involved in MICB shedding of PANC-1 cells and that gemcitabine inhibits MICB ectodomain shedding through the suppression of ADAM15.

View Figures

View References

1	Sargent M, Boeck S, Heinemann V, Jauch KW, Seufferlein T and Bruns CJ: Surgical treatment concepts for patients with pancreatic cancer in Germany - results from a national survey conducted among members of the ‘Chirurgische Arbeitsgemeinschaft Onkologie’ (CAO) and the ‘Arbeitsgemeinschaft Internistische Onkologie’ (AIO) of the Germany Cancer Society (DKG). Langenbecks Arch Surg. 396:223–229. 2011.PubMed/NCBI
2	Hackert T, Büchler MW and Werner J: Surgical options in the management of pancreatic cancer. Minerva Chir. 64:465–476. 2009.PubMed/NCBI
3	Siegel R, Desantis C, Virgo K, et al: Cancer treatment and survivorship statistics, 2012. CA Cancer J Clin. 62:220–241. 2012. View Article : Google Scholar : PubMed/NCBI
4	Levi F, Lucchini F, Negri E and La Vecchia C: Pancreatic cancer mortality in Europe: the leveling of an epidemic. Pancreas. 27:139–142. 2003. View Article : Google Scholar : PubMed/NCBI
5	Waldmann TA: Immunotherapy: past, present and future. Nat Med. 9:269–277. 2003. View Article : Google Scholar : PubMed/NCBI
6	Dranoff G: Coordinated tumor immunity. J Clin Invest. 111:1116–1118. 2003. View Article : Google Scholar : PubMed/NCBI
7	Groh V, Rhinehart R, Secrist H, Bauer S, Grabstein KH and Spies T: Broad tumor-associated expression and recognition by tumor-derived gamma delta T cells of MICB and MICB. Proc Natl Acad Sci USA. 96:6879–6884. 1999. View Article : Google Scholar : PubMed/NCBI
8	González S, Groh V and Spies T: Immunobiology of human NKG2D and its ligands. Curr Top Microbiol Immunol. 298:121–138. 2006.
9	Wu JD, Higgins LM, Steinle A, Cosman D, Haugk K and Plymate SR: Prevalent expression of the immunostimulatory MHC class I chain-related molecule is counteracted by shedding in prostate cancer. J Clin Invest. 114:560–568. 2004. View Article : Google Scholar : PubMed/NCBI
10	Ohashi M, Yoshida K, Kushida M, et al: Adenovirus-mediated interferon gene transfer induces regional direct cytotoxicity and possible systemic immunity against pancreatic cancer. Br J Cancer. 93:441–449. 2005. View Article : Google Scholar
11	Märten A, von Lilienfeld-Toal M, Büchler MW and Schmidt J: Soluble MIC is elevated in the serum of patients with pancreatic carcinoma diminishing gammadelta T cell cytotoxicity. Int J Cancer. 119:2359–2365. 2006.PubMed/NCBI
12	Diefenbach A, Jensen ER, Jamieson AM and Raulet DH: Rae1 and H60 ligands of the NKG2D receptor stimulate tumour immunity. Nature. 413:165–171. 2001. View Article : Google Scholar : PubMed/NCBI
13	Groh V, Wu J, Yee C and Spies T: Tumour-derived soluble MIC ligands impair expression of NKG2D and T-cell activation. Nature. 419:734–738. 2002. View Article : Google Scholar : PubMed/NCBI
14	Salih HR, Goehlsdorf D and Steinle A: Release of MICB molecules by tumor cells: mechanism and soluble MICB in sera of cancer patients. Hum Immunol. 67:188–195. 2006. View Article : Google Scholar : PubMed/NCBI
15	Boutet P, Agüera-González S, Atkinson S, et al: Cutting edge: the metalloproteinase ADAM17/TNF-alpha-converting enzyme regulates proteolytic shedding of the MHC class I-related chain B protein. J Immunol. 182:49–53. 2009. View Article : Google Scholar : PubMed/NCBI
16	Hidalgo M: Pancreatic cancer. N Engl J Med. 362:1605–1617. 2010. View Article : Google Scholar
17	Plate JM, Plate AE, Shott S, Bograd S and Harris JE: Effect of gemcitabine on immune cells in subjects with adenocarcinoma of the pancreas. Cancer Immunol Immunother. 54:915–925. 2005. View Article : Google Scholar : PubMed/NCBI
18	Li K, Mandai M, Hamanishi J, et al: Clinical significance of the NKG2D ligands, MICA/B and ULBP2 in ovarian cancer: high expression of ULBP2 is an indicator of poor prognosis. Cancer Immunol Immunother. 58:641–652. 2009. View Article : Google Scholar : PubMed/NCBI
19	Schütz A, Härtig W, Wobus M, Grosche J, Wittekind Ch and Aust G: Expression of ADAM15 in lung carcinomas. Virchows Arch. 446:421–429. 2005.
20	Chen X, Liao J, Lu Y, Duan X and Sun W: Activation of the PI3K/Akt pathway mediates bone morphogenetic protein 2-induced invasion of pancreatic cancer cells PANC-1. Pathol Oncol Res. 17:257–261. 2011. View Article : Google Scholar : PubMed/NCBI
21	Holdenrieder S, Stieber P, Peterfi A, Nagel D, Steinle A and Salih HR: Soluble MICB in malignant diseases: analysis of diagnostic significance and correlation with soluble MICA. Cancer Immunol Immunother. 55:1584–1589. 2006. View Article : Google Scholar : PubMed/NCBI
22	Kaiser BK, Yim D, Chow IT, et al: Disulphide-isomerase-enabled shedding of tumour-associated NKG2D ligands. Nature. 447:482–486. 2007. View Article : Google Scholar : PubMed/NCBI
23	Najy AJ, Day KC and Day ML: The ectodomain shedding of E-cadherin by ADAM15 supports ErbB receptor activation. J Biol Chem. 283:18393–18401. 2008. View Article : Google Scholar : PubMed/NCBI
24	Lucas N, Najy AJ and Day ML: The therapeutic potential of ADAM15. Curr Pharm Des. 15:2311–2318. 2009. View Article : Google Scholar
25	Heinemann V, Boeck S, Hinke A, Labianca R and Louvet C: Meta-analysis of randomized trials: evaluation of benefit from gemcitabine-based combination chemotherapy applied in advanced pancreatic cancer. BMC Cancer. 8:822008. View Article : Google Scholar
26	Abou-Alfa GK, Letourneau R, Harker G, et al: Randomized phase III study of exatecan and gemcitabine compared with gemcitabine alone in untreated advanced pancreatic cancer. J Clin Oncol. 24:4441–4447. 2006. View Article : Google Scholar : PubMed/NCBI
27	Yanagimoto H, Shiomi H, Satoi S, et al: A phase II study of personalized peptide vaccination combined with gemcitabine for non-resectable pancreatic cancer patients. Oncol Rep. 24:795–801. 2010.PubMed/NCBI
28	Koido S, Homma S, Takahara A, et al: Current immunotherapeutic approaches in pancreatic cancer. Clin Dev Immunol. 2011:2675392011. View Article : Google Scholar : PubMed/NCBI